ReMemBr Group studies

Currently recruiting clinical studies:

COBALT
ComBining memantine And cholinesterase inhibitors in Lewy body dementia Treatment trial (COBALT) is a clinical trial which aims to find out if adding Memantine to a cholinesterase inhibitor (either donepezil, rivastigmine and galantamine improves overall health and functioning for people with Dementia with Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD). 
 
Enrol-HD
Enroll-HD is a clinical research platform and the world’s largest observational study for Huntington’s disease families. It is a resource for the entire HD community, including families, clinicians, researchers, advocates, and anyone else who has a connection to or an interest in HD.
 
Fastball
This is a study to assess the accuracy and sensitivity of using electroencephalography (EEG) for the diagnosis of Alzheimer’s disease. It involves easy-to-use headsets to measure brain activity, while patients view a stream of images on a screen. It is led by the University of Bath in collaboration with the University of Bristol, North Bristol Trust and Cumulus Neuroscience Limited, and is funded by NIHR Invention for Innovation (i4i) Programme.
 
Mild Cognitive Impairment-Core Outcomes Study
A study looking for individuals diagnosed with mild cognitive impairment (MCI), or people who have experience caring for, working with, or living with people with MCI. Led by University of Bristol, and funded by NIHR. 
 
ON-FIRE

Open Network for Frontotemporal dementia Inflammation Research (ON-FIRE) is a multi-centre study that aims to identify clinically relevant inflammatory profiles in people with Frontotemporal dementia, and to investigate the genetic and environmental factors which influence these patterns. Led by Dementias Platform UK (DPUK) with multiple sites including the Brain Centre, North Bristol Trust.

READ-OUT

The REAl world Dementia OUTcomes (READ-OUT) study is aimed at identifying blood tests that could help diagnose Alzheimer’s disease and other forms of dementia more accurately and quickly than current methods. READ-OUT is led by Dementias Platform UK (DPUK), with multiple UK sites including the Brain Centre, North Bristol Trust. It is part of the Blood Biomarker Challenge – a multi-million-pound programme supported by Alzheimer’s Society, Alzheimer’s Research UK, National Institute for Health and Care Research, Gates Ventures and players of People’s Postcode Lottery.

SAM

The Sleep Apnoea and Memory (SAM) study aims to find out how many people who attend memory clinics have sleep apnoea, improve recognition of which symptoms are linked to sleep apnoea, and see if these can be measured in people's own homes. It is led by University of Bristol and funded by NIHR. 

Sleep-AD (sub-study 2)

A clinical study to assess the accuracy of blood biomarkers for the diagnosis of Alzheimer’s disease in patients undergoing cognitive assessment at the Brain Centre, North Bristol Trust, involving routine lumbar puncture (cerebrospinal fluid) and blood samples. It is funded by Rosetrees Trust.

 

Closed to recruitment but ongoing:

Mysmile 

If you are interested in taking part in these studies, please email researchvolunteer@nbt.nhs.uk or telephone: 0117 414933

For more information about currently open studies see North Bristol Trust Research